By Professor Michael Leonard Friedlander

Journal articles

Friedlander ML; Hedley DW; Swanson C; Russell P, 1988, 'Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer', Journal of Clinical Oncology, 6, pp. 282 - 290, http://dx.doi.org/10.1200/JCO.1988.6.2.282

Trebeck CE; Friedlander ML; Russell P; Baird PJ, 1987, 'Brenner tumours of the ovary: A study of the histology, immunohistochemistry and cellular dna content in benign, borderline and malignant ovarian tumours', Pathology, 19, pp. 241 - 246, http://dx.doi.org/10.3109/00313028709066557

KIRSTEN F; ATKINSON KH; COPPLESON JVM; ELLIOTT PM; GREEN D; HOUGHTON R; MURRAY JC; RUSSELL P; SOLOMON HJ; FRIEDLANDER M; SWANSON CE; TATTERSALL MHN, 1987, 'Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer', BJOG: An International Journal of Obstetrics & Gynaecology, 94, pp. 583 - 588, http://dx.doi.org/10.1111/j.1471-0528.1987.tb03154.x

Zalcberg JR; Friedlander ML; Minden MD, 1986, 'Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia', British Journal of Cancer, 53, pp. 459 - 464, http://dx.doi.org/10.1038/bjc.1986.73

Friedlander M; Zalcberg J; Patterson B; Minden M; Bergsagel DE, 1985, 'APPARENT T-CELL NEOPLASMS WITH IMMUNOGLOBULIN GENE REARRANGEMENTS', The Lancet, 326, pp. 670, http://dx.doi.org/10.1016/S0140-6736(85)90036-4

Taylor IW; Slowiaczek P; Friedlander ML; Tattersall MHN, 1985, 'Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-resistant Cells with Reduced Drug Uptake', Cancer Research, 45, pp. 978 - 982

Hedley DW; Friedlander ML; Taylor IW, 1985, 'Application of DNA flow cytometry to paraffin‐embedded archival material for the study of aneuploidy and its clinical significance', Cytometry, 6, pp. 327 - 333, http://dx.doi.org/10.1002/cyto.990060409

Eckstein RP; Russell P; Friedlander ML; Tattersall MHN; Bradfield A, 1985, 'Metastasizing placental site trophoblastic tumor: A case study', Human Pathology, 16, pp. 632 - 636, http://dx.doi.org/10.1016/S0046-8177(85)80114-3

Friedlander ML; Russell P; Taylor IW; Tattersall MHN, 1985, 'Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer', British Journal of Cancer, 51, pp. 319 - 333, http://dx.doi.org/10.1038/bjc.1985.44

Friedlander M; Foo MS; Quinn M, 1985, 'Relationship of steroid receptors and tumor ploidy in epithelial ovarian cancer', Proceedings of the American Association for Cancer Research, VOL. 26

Friedlander ML; Taylor IW; Russell P; Tattersall MH, 1984, 'Cellular DNA content—a stable feature in epithelial ovarian cancer', British Journal of Cancer, 49, pp. 173 - 179, http://dx.doi.org/10.1038/bjc.1984.29

Friedlander ML; Hedley DW; Taylor IW, 1984, 'Clinical and biological significance of aneuploidy in human tumours', Journal of Clinical Pathology, 37, pp. 961 - 974, http://dx.doi.org/10.1136/jcp.37.9.961

Hedley DW; Friedlander ML; Taylor IW; Rugg CA; Musgrove EA, 1984, 'DNA flow cytometry of paraffin‐embedded tissue', Cytometry, 5, pp. 660 - 660, http://dx.doi.org/10.1002/cyto.990050618

Friedlander ML; Russell P; Taylor IW; Hedley DW; Tattersall MHN, 1984, 'Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy', Pathology, 16, pp. 301 - 306, http://dx.doi.org/10.3109/00313028409068541

Hedley DW; Taylor IW; Coates AS; Tattersall MHN; Russell P; Friedlander ML, 1984, 'Influence of Cellular DNA Content on Survival in Advanced Ovarian Cancer', Cancer Research, 44, pp. 397 - 400

Friedlander ML, 1984, 'Prognostic Variables in Epithelial Ovarian Cancer: A Review', Australian and New Zealand Journal of Obstetrics and Gynaecology, 24, pp. 256 - 261, http://dx.doi.org/10.1111/j.1479-828X.1984.tb01506.x

Friedlander ML; Atkinson K; Coppleson JVM; Elliot P; Green D; Houghton R; Solomon HJ; Russell P; Tattersall MHN, 1984, 'The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study', Gynecologic Oncology, 19, pp. 1 - 7, http://dx.doi.org/10.1016/0090-8258(84)90150-1

Friedlander ML; Sims K; Kearsley JH, 1983, 'IMPAIRMENT OF RECALL IMPROVES TOLERANCE OF CYTOTOXIC CHEMOTHERAPY', The Lancet, 322, pp. 686, http://dx.doi.org/10.1016/S0140-6736(83)92568-0

Friedlander M; Kaye SB; Sullivan A; Atkinson K; Elliott P; Coppleson M; Houghton R; Solomon J; Green D; Russell P; Hudson CN; Langlands AO; Tattersall MHN, 1983, 'Cervical carcinoma: A drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy', Gynecologic Oncology, 16, pp. 275 - 281, http://dx.doi.org/10.1016/0090-8258(83)90102-6

FRIEDLANDER ML; KEARSLEY JH; SIMS K; COATES A; HEDLEY D; RAGHAVAN D; FOX RM; TATTERSALL MHN, 1983, 'LORAZEPAM AS AN ADJUNCT TO ANTIEMETIC THERAPY WITH HALOPERIDOL IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY', Australian and New Zealand Journal of Medicine, 13, pp. 53 - 56, http://dx.doi.org/10.1111/j.1445-5994.1983.tb04550.x

, 1983, 'Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry', Journal of Histochemistry and Cytochemistry, 31, pp. 1333 - 1335, http://dx.doi.org/10.1177/31.11.6619538

Friedlander ML; Taylor IW; Russell P; Musgrove EA; Hedley DH; Tattersall MHN, 1983, 'Ploidy as a prognostic factor in ovarian cancer', International Journal of Gynecological Pathology, 2, pp. 55 - 63, http://dx.doi.org/10.1097/00004347-198301000-00005

Taylor IW; Musgrove EA; Friedlander ML; Foo MS; Hedley DW, 1983, 'The influence of age on the DNA ploidy levels of breast tumours', European Journal of Cancer and Clinical Oncology, 19, pp. 623 - 628, http://dx.doi.org/10.1016/0277-5379(83)90178-5

Tattersall MH; Friedlander ML, 1982, 'Cost considerations in cancer chemotherapy.', Australian health review : a publication of the Australian Hospital Association, 5, pp. 21 - 24

Friedlander ML; Tattersall MHN, 1982, 'Counting the costs of cancer therapy', European Journal of Cancer and Clinical Oncology, 18, pp. 1237 - 1241, http://dx.doi.org/10.1016/0277-5379(82)90124-9

Raghavan D; Coates A; Friedlander M, 1982, 'Mitoxantrone (XAN): Progress in a phase ii trial in Sydney, Australia', Proceedings of the American Society of Clinical Oncology, Vol. 1

Friedlander ML; Halley JBW; Sinosich MJ; Coates A, 1982, 'Pulmonary Pseudotumours Following Chemotherapy for Endodermal Sinus Tumour of the Ovary', Australian and New Zealand Journal of Obstetrics and Gynaecology, 22, pp. 110 - 112, http://dx.doi.org/10.1111/j.1479-828X.1982.tb01417.x

Friedlander M; Tattersall MHN, 1981, 'Postoperative radiotherapy in breast cancer', British Medical Journal (Clinical research ed.), 282, pp. 2133 - 2134, http://dx.doi.org/10.1136/bmj.282.6282.2133-d

Friedlander M; Kearsley JH; Tattersall MHN, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTOTOXIC THERAPY', The Lancet, 317, pp. 1316 - 1317, http://dx.doi.org/10.1016/S0140-6736(81)92489-2

Friedlander ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC CANCER', The Lancet, 316, pp. 1373, http://dx.doi.org/10.1016/S0140-6736(80)92440-X

FRIEDLANDER ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC-CANCER', LANCET, 2, pp. 1373 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KU80600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Ajipa O; Su F; Han Y; Matulonis U, 2022, 'TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer', in E-Posters (Trials In Progress), BMJ Publishing Group Ltd, pp. A238.1 - A238, presented at IGCS 2022 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2022-igcs.539

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wildiers H; Ayoub J-P; Friedlander M; Kaufman B; Arun BK; Han HS; Puhalla SL; Maag D; Feng D; Ratajczak CK; Bach BA; Diéras V, 2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03

Colombo N; Bradley W; Moore K; Gonzalez-Martin A; Scambia G; Oaknin A; Friedlander M; Lowe E; Rowe P; Disilvestro P, 2020, 'MAINTENANCE OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: SUBGROUP ANALYSIS BY RISK IN THE PHASE III SOLO1 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A76 - A77, http://dx.doi.org/10.1136/ijgc-2020-ESGO.130

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; Disilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1334 - S1334, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.228

Meiser B; Gleeson M; Kentwell M; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill Y; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker K, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Swisher EM; Coleman RL; Bookman MA; Brady MF; Fleming GF; Friedlander M; Cunningham MJ; Tewari KS; Edraki B; Moxley K; Mantia-Smaldone GM; Ratajczak C; Dinh MH; Sullivan DM; McClain S; Okubo S; Steffensen KD; Aghajanian C, 2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040

Banerjee S; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; Gonzalez Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; DiSilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S613 - S613, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.950

Yoon W-H; Kok PS; Marschner I; Lord S; Friedlander M; Lee CK, 2020, 'Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S715 - S715, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1162

Macdonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper J; Friedlander M; Emery J; Phillips KA, 2020, 'The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S958 - S958, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2057

Ayoub J-P; Friedlander ML; Dieras VC; Wildiers H; Arun B; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Kundu MG; Wu M; Ratajczak C; Maag D; Kaufman B, 2020, 'Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S65 - S65, presented at ESMO Breast Cancer Virtual Meeting, ELECTR NETWORK, 23 May 2020 - 24 May 2020, http://dx.doi.org/10.1016/j.annonc.2020.03.241

Sivakumaran T; Krasovitsky M; Freimund A; Chen Lee K; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, '402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, pp. A166.2 - A167, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.347

Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, pp. A167.1 - A167, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.348

Friedlander ML, 2019, 'Do all patients with recurrent ovarian cancer need systemic therapy?', in Cancer, pp. 4602 - 4608, http://dx.doi.org/10.1002/cncr.32476

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bach BA; Dudley M; Ratajczak CK; Maag D; Dieras V, 2019, 'First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD4-01

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2019, 'Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1557-3265.ovcasymp18-gmm-048

Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'MAINTENANCE OLAPARIB AFTER PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: EFFICACY BY THE TIMING OF SURGERY AND RESIDUAL TUMOUR STATUS FOLLOWING UPFRONT OR INTERVAL CYTOREDUCTIVE SURGERY IN THE PHASE III SOLO1 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A14 - A15, http://dx.doi.org/10.1136/ijgc-2019-ESGO.17

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, pp. CT084 - CT084, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

Back to profile page